<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-552
Date of Submission: 2025-05-06

This report was submitted by a Physician from Adams-Parks Medical Center concerning patient ANON-PX-1845. The subject is a 52-year-old female with a significant medical history including anxiety, seasonal allergies, migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Subcutaneous route at a dosage of 211mg, initiated on 2025-02-07 for Bacterial infection with the course ongoing; Atorvastatin (Statin) administered via the Topical route at a dosage of 195mg, initiated on 2025-02-07 for Hypercholesterolemia with the course ongoing.

On approximately 2025-04-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Anaphylaxis. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed past and advised cover. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed eye and advised million. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Authority light civil discuss democratic. Station million color blood watch.</data>
report_id: ADR-2025-552
report_date: '2025-05-06'
patient_details:
  patient_id: ANON-PX-1845
  gender: Female
  relevant_history:
  - anxiety
  - seasonal allergies
  - migraines
  - type 2 diabetes
  age_at_reaction: 52
suspected_drugs:
- drug_name: Amoxicillin
  dosage: 211mg
  route_of_administration: Subcutaneous
  start_date: '2025-02-07'
  indication_for_use: Bacterial infection
  drug_class: Penicillin antibiotic
- drug_name: Atorvastatin
  dosage: 195mg
  route_of_administration: Topical
  start_date: '2025-02-07'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-04-11'
  severity: Mild
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed past and advised cover.
- symptom_name: Anaphylaxis
  onset_date: '2025-04-11'
  severity: Severe
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed eye and advised million.
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
reporting_facility: Adams-Parks Medical Center
reporter_type: Physician
notes: Authority light civil discuss democratic. Station million color blood watch.
